Latest Headlines

Latest Headlines

J&J, Amazon fight shows supply-chain weakness in online sales

Consumers who purchase over-the-counter products like Tylenol online sometimes receive items that are expired, defective, or even counterfeit. Now Johnson & Johnson and Amazon are in a fight over how much the online giant should be doing to keep that from happening.

J&J follows up on pledge to add warning to Tylenol bottle caps

The FDA has pushed makers of the nonaspirin pain reliever acetaminophen to do more to warn consumers about the dangers of the drug when taken in high doses. J&J is now adding warnings to Tylenol bottle caps in response.

Pfizer, Merck, J&J all close books on some lawsuits

It has been a week of conciliation among some of the Big Pharma players, with Pfizer settling more Chantix litigation, Merck closing out some Vioxx lawsuits and Johnson & Johnson coming to terms with shareholders angered over its handling of Tylenol recalls.

J&J consumer healthcare faces more issues, this time in Brazil

Johnson & Johnson just can't seem to get its consumer health manufacturing in order.

J&J issue in South Korea reminiscent of OTC problems here

Drugmakers hope to export their success to emerging markets so they can reap big rewards, but Johnson & Johnson's Janssen unit appears to have taken a backward approach in South Korea, where it is in hot water over a recall of Children's Tylenol products.

J&J consent decree cost felt at the pharmacy

Johnson & Johnson, whose McNeil Consumer Healthcare is operating under an FDA consent decree, is taking a sales hit this flu season as consumers go to some pharmacies and find few or no Tylenol products on the shelves.

Tired of empty shelves, CVS stops stocking Tylenol in some stores

CVS, the drugstore chain, will stop stocking Tylenol in some of its stores. Ongoing supply problems have store shelves still empty, and CVS wants to fill those holes.

India kicks branded generics to the curb

Drugmakers, get ready to revise your playbooks. Branded generics may be a no-go in India. Continuing their assault on drug costs, government officials are rolling out a new generics-only licensing policy. New off-patent drugs would win approval under their generic names only.

J&J 'decree' upgrades cost 200 jobs in Puerto Rico

Improvements being made at a plant in Puerto Rico as Johnson & Johnson ($JNJ) checks off the requirements of a consent decree with the FDA are going to cost nearly 25% of its workers their jobs.

J&J ramping up OTC production as 'decree' work allows

Alex Gorsky, in his first earnings call since taking the CEO spot at Johnson & Johnson, listed a lot of priorities--there is a lot to be fixed at the pharmaceutical and consumer products company--but getting over-the-counter products like Tylenol and Motrin back into the hands of consumers remains his number one "short term priority."